Focus Partners Wealth
GALT icon

Focus Partners Wealth’s Galectin Therapeutics GALT Stock Holding History

Focus Partners Wealth’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,897
Closed -$38.8K – 2851
2026
Q1 		$38.8K Buy
13,897
+1,301
+10% +$3.96K ﹤0.01% 2591
2025
Q4 		$52.4K Buy
12,596
+334
+3% +$1.76K ﹤0.01% 2600
2025
Q3 		$51.9K Sell
12,262
-1,054
-8% -$3.96K ﹤0.01% 2160
2025
Q2 		$28.1K Sell
13,316
-14
-0.1% -$21 ﹤0.01% 1994
2025
Q1 		$16.3K Sell
13,330
-1,921
-13% -$2.69K ﹤0.01% 1877
2024
Q4 		$19.7K Sell
15,251
-1,483
-9% -$3.55K ﹤0.01% 1849
2024
Q3 		$46K Buy
+16,734
New +$41.1K ﹤0.01% 1544

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Focus Partners Wealth's GALT Position: Q2 2026 in Review

Focus Partners Wealth sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 13,897 shares — an estimated $38.8K sold.

Focus Partners Wealth first reported a position in GALT in Q3 2024 and held it in 7 quarters. The position peaked at $52.4K in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Focus Partners Wealth reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 13,897 Galectin Therapeutics shares in Q2 2026, an estimated $38.8K.
  • Focus Partners Wealth first reported a position in Galectin Therapeutics in Q3 2024 and held it in 7 quarters.
  • Focus Partners Wealth's Galectin Therapeutics position peaked at $52.4K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.